Ann D Rhoads
CIK 1250252 · Chief Financial Officer · last filed 2026-11-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GMED price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN JOSE, CA 95134
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GMED | Director | 35,384 | $76.23 | $2.70M | -$3.47M | 23 | 2026-11-05 |
| QDEL | Director | 23,257 | $11.89 | $276.5K | $21.2K | 20 | 2026-06-29 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 0 | $2.65 | $0 | $80.0K | 7 | 2026-01-28 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | Director | — | $10.15 | — | $0 | 7 | 2025-08-29 |
| Evoke Pharma Inc (EVOK) Delisted | Director | — | $11.00 | — | $0 | 3 | 2021-07-23 |
| Forty Seven, Inc. (FTSV) Delisted | Chief Financial Officer | 0 | — | — | -$183.6K | 3 | 2020-04-07 |
| IRIX | Director | 5,690 | $0.71 | $4.1K | $0 | 3 | 2018-06-15 |
| Evoke Pharma Inc (OMED) Delisted | Director | — | — | — | $0 | 5 | 2018-04-27 |
| ZOGENIX, INC. (ZGNX) Delisted | EVP, CFO, Treasurer & Sec. | 24,901 | $26.68 | $664.4K | $220.8K | 11 | 2016-03-16 |
| NOVELLUS SYSTEMS INC (NVLS) Delisted | Director | 8,750 | — | — | $0 | 5 | 2011-05-13 |
Recent Filings · Page 3 of 10
95 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-03-28 | GMED | Grant (A) | — | $0 | EDGAR |
| 2025-03-04 | GMED | Sell (S) | −7,500 | -$590.1K | EDGAR |
| 2025-02-28 | GMED | Notice (144) | −7,500 | -$590.0K | EDGAR |
| 2024-09-17 | GMED | Mixed | +20,000 | -$183.5K | EDGAR |
| 2024-09-13 | GMED | Notice (144) | −15,000 | -$1.05M | EDGAR |
| 2024-06-20 | Repare Therapeutics Inc. (RPTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-13 | iTeos Therapeutics, Inc. (ITOS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-10 | QDEL | Mixed | +1,220 | $0 | EDGAR |
| 2024-05-29 | QDEL | Mixed | +2,416 | $0 | EDGAR |
| 2024-05-23 | QDEL | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.